<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05031871</url>
  </required_header>
  <id_info>
    <org_study_id>HR17031-102</org_study_id>
    <nct_id>NCT05031871</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of HR17031 Injection in Healthy Subjects</brief_title>
  <official_title>Pharmacokinetic Study of HR17031 Injection in Healthy Subjects (Single-center, Randomized, Open-label, 4 Cycles, 4 Sequences)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the pharmacokinetics and safety of HR17031 injection, SHR20004 injection and/or&#xD;
      INS068 injection in healthy subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 2, 2021</start_date>
  <completion_date type="Anticipated">October 8, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 8, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax：Maximum observed concentration</measure>
    <time_frame>Day1 to Day 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t ：Area under the curve from the time of dosing time to the last measurable (positive) concentration；</measure>
    <time_frame>Day1 to Day 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf：Area under the curve from time 0 to infinity；</measure>
    <time_frame>Day1 to Day 26</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax ：time of maximum observed concentration</measure>
    <time_frame>Day1 to Day 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2：Half-life time ；</measure>
    <time_frame>Day1 to Day 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>Day1 to Day 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F</measure>
    <time_frame>Day1 to Day 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum glucose within 24h after injection</measure>
    <time_frame>Day1 to Day 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide concentrations within 24h after injection</measure>
    <time_frame>Day1 to Day 23</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADA：anti-drug antibody</measure>
    <time_frame>Day 1、Day 8、Day15、Day 22 or early termination</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Treatment group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HR17031 injection dose+INS068 injection dose+SHR20004 injection dose+(INS068+SHR20004) injection dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INS068 injection dose+(INS068+SHR20004)injection dose+ HR17031 injection dose +SHR20004 injection dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR20004 injection dose+ HR17031 injection dose +(INS 068+SHR20004) injection dose+ INS068 injection dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(INS 068+SHR20004) injection dose+ SHR20004 injection dose+ INS068 injection dose+ HR17031 injection dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HR17031 injection ；INS068 injection；SHR20004 injection</intervention_name>
    <description>HR17031 injection dose+INS068 injection dose+SHR20004 injection dose+(INS068+SHR20004) injection dose</description>
    <arm_group_label>Treatment group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HR17031 injection ；INS068 injection；SHR20004 injection</intervention_name>
    <description>INS068 injection dose+(INS068+SHR20004)injection dose+ HR17031 injection dose +SHR20004 injection dose</description>
    <arm_group_label>Treatment group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HR17031 injection ；INS068 injection；SHR20004 injection</intervention_name>
    <description>SHR20004 injection dose+ HR17031 injection dose +(INS 068+SHR20004) injection dose+ INS068 injection dose</description>
    <arm_group_label>Treatment group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HR17031 injection ；INS068 injection；SHR20004 injection</intervention_name>
    <description>(INS 068+SHR20004) injection dose+ SHR20004 injection dose+ INS068 injection dose+ HR17031 injection dose</description>
    <arm_group_label>Treatment group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Body mass index (BMI) ranges from 18 to 27 kg/m2 (both ends included), and the body&#xD;
             weight is ≥50 kg for men and ≥45 kg for women；&#xD;
&#xD;
          2. Fasting blood glucose during the screening is &lt; 6.1 mmol/L；&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. It has clinical significance for abnormalities Laboratory examination, if there is a&#xD;
             clear reasonable reason, can be retested within a week, with the retest results&#xD;
             Whether the subject meets the requirements&#xD;
&#xD;
          2. Severe systemic disease, or a prior history of pancreatitis or other systemic problems&#xD;
             within 1 month prior to screening;&#xD;
&#xD;
          3. Participate in any clinical trial of a drug or medical device within 3 months prior to&#xD;
             screening (subject to signed informed consent)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

